Table 4.
Demographic and disease characteristics of the patients in the series and according to presence of intermediate/high tumor budding (≥5 buds per 20× power field in a hotspot area of 0.785 mm2).
| Category | Total (%) (n = 75) |
Low Tumor Budding (n = 39) |
Intermediate/High Tumor Budding (n = 36) | x 2 | |
|---|---|---|---|---|---|
| AGE | Mean | 58.9 | 59.1 | 58.8 | p = 0.8 |
| ≤65 | 52 (69.3%) | 28 (71.8%) | 24 (66.7%) | p = 0.8 | |
| >65 | 23 (30.7%) | 11(28.2%) | 12 (33.3%) | ||
| MENOPAUSE STATUS | Pre-/perimenopausal | 19 (25.3%) | 11 (28.2%) | 8 (22.2%) | p = 0.7 |
| Post-menopausal | 56 (74.7%) | 28 (71.8%) | 28 (77.8%) | ||
| CLINICAL STAGE | I | 3 (4%) | 1 (2.6%) | 2 (5.6%) | p = 0.6 |
| II | 52 (69.3%) | 26 (66.7%) | 26 (72.2%) | ||
| III | 20 (26.7%) | 12 (30.7%) | 8 (22.2%) | ||
| ER | positive | 58 (77.3%) | 29 (74.4%) | 29 (80.6%) | p = 0.7 |
| negative | 17 (22.7%) | 10 (25.6%) | 7 (19.4%) | ||
| PR | positive | 47 (62.7%) | 24 (61.5%) | 23 (63.9%) | p = 0.8 |
| negative | 28 (37.3%) | 15 (38.5%) | 13 (36.1%) | ||
| HER2 | positive | 23 (30.7%) | 12 (30.7%) | 11 (30.6%) | p = 0.9 |
| negative | 52 (69.3%) | 27 (69.3%) | 25 (69.4%) | ||
| SUB-TYPE | ER+/ HER2− | 41 (54.7%) | 22 (56.4%) | 19 (52.7%) | |
| HER2+ | 24 (32%) | 13 (33.3%) | 11 (30.6%) | p = 0.7 | |
| Triple Negative | 10 (13.3%) | 4 (10.3%) | 6 (16.7%) | ||
| HISTOLOGY (n = 74) | Ductal | 58 (78.4%) | 32 (82%) | 26 (74.3%) | |
| Lobular | 10 (13.5%) | 4 (10.3%) | 6 (17.1%) | p = 0.7 | |
| Mixed | 5 (6.8%) | 2 (5.1%) | 3 (8.6%) | ||
| Other | 1 (1.3%) | 1 (2.6%) | 0 | ||
| RESPONSE (n = 72) | CR | 15 (20.8%) | 8 (21%) | 7 (20.6%) | p = 0.69 |
| PR | 20 (27.8%) | 9 (23.7%) | 11 (32.3%) | ||
| NR | 37 (51.4%) | 21 (55.3%) | 16 (47.1%) |